Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic B7.1/HLA-A1 vaccine for NSCLC
NCT00534209Phase 2Terminated
- Sponsor
- University of Miami
- Start
- Jan 2009
- Primary completion
- Apr 2010
- Modality
- Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic B7.1/HLA-A1 vaccine in non-small cell lung cancer (NSCLC), sponsored by University of Miami. Started Jan 2009; status: terminated.
02
Drugs
allogeneic B7.1/HLA-A1 vaccine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00534209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00534209.